These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27311933)

  • 41. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
    Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
    Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic models in myelodysplastic syndromes.
    Bejar R
    Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
    Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
    Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients.
    Masuda K; Shiga S; Kawabata H; Takaori-Kondo A; Ichiyama S; Kamikubo Y
    Int J Hematol; 2018 Jul; 108(1):30-38. PubMed ID: 29600427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
    Nazha A; Bejar R
    Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
    Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
    Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Revised international prognostic scoring system for myelodysplastic syndromes.
    Greenberg PL; Tuechler H; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Malcovati L; Cazzola M; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres M; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D
    Blood; 2012 Sep; 120(12):2454-65. PubMed ID: 22740453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.
    Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
    Singhal D; Wee LYA; Kutyna MM; Chhetri R; Geoghegan J; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Hiwase S; Edwards S; Moore S; Branford S; Kuzmanovic T; Singhal N; Gowda R; Brown AL; Arts P; To LB; Bardy PG; Lewis ID; D'Andrea RJ; Maciejewski JP; Scott HS; Hahn CN; Hiwase DK
    Leukemia; 2019 Dec; 33(12):2842-2853. PubMed ID: 31089247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
    Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
    J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Molecular international prognostic scoring system for myelodysplastic syndromes].
    Nagata Y
    Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
    Wei J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
    Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
    Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
    Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
    Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
    Komrokji RS; Corrales-Yepez M; Al Ali N; Kharfan-Dabaja M; Padron E; Fields T; Lancet JE; List AF
    Cancer; 2012 May; 118(10):2659-64. PubMed ID: 21956402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.